GMAB
Source profileGenmab
Antibody medicines
Company profile
CIK1434265
ExchangeNASDAQ Copenhagen
SectorHealthcare
Tracked assets1
Pipeline assets
Epcoritamab
Lymphoma
Approved/Phase 3ASCO
Upcoming and past catalysts
| Company | Catalyst | Asset | Phase | Expected | Confidence | Status |
|---|---|---|---|---|---|---|
| GMAB Genmab | Conference update on combination cohorts ASCO | Epcoritamab | Approved/Phase 3 | ASCO 2026 | exact | upcoming |
SEC filings
No sample filings for this company.
Press releases
ClinicalTrials.gov studies
No linked sample studies for this company.